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Abstract 
Introduction: Purple glove syndrome is an atypical and adverse reaction to intravenous
phenytoin, which is characterized by oedema, pain and a dark purple-bluish discolouration,
typically located on an upper extremity. The clinical manifestation of this syndrome occurs
in three stages: appearance, progression and resolution of symptoms. PGS develops up to 12
hours  after  administration  of  intravenous  phenytoin  and it  disappears  in  a  few weeks or
months.
Objective: The aim of this article is to summarize the current state of knowledge about
purple  glove  syndrome:  the  pathophysiology,  risk  factors,  the  diagnosis  and  the  current
treatment.
Brief  descriptions  of  the  state  of  knowledge:  Despite  many  years  PGS  is  still
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unexplained phenomenon. It is claimed that vascular tearing, micro-extravasation, alkaline
pH of the solution or unidentified procoagulant mechanism can cause tissue impairment. The
treatment depends on a limb elevation, physiotherapy,  intravenous heparin administration,
pain  control,  nitroglycerine  application  and  a  nerve  blocks.  To  prevent  PGS  it  is
recommended to use oral phenytoin whenever possible, slow infusion rate of phenytoin less
than 25mg/min,  large cannula (20G or larger)  in a large  calibre vein and suitable,  small
doses. What is important fosphenytoin, a pro-drug of phenytoin, can also cause PGS, even
though  it  was  thought  to  be  a  safe  drug,  and  a  purple  glove  syndrome  induced  by
fosphenytoin has never been described before. 
Summary:  Despite  the  existence  of  many  clinical  trials,  long  term  observations  and
scientific speculations, PGS can still be challenging  for clinicians. There is a need for further
scientific research to explain this phenomenon and to increase the awareness of this problem
in general medical practice.
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Introduction
Phenytoin, as a well-known, nonsedative anticonvulsant,  has been associated with a number
of  serious  adverse  drug  reactions,   including  hypotension  and  arrhythmias  after  rapid
intravenous  administration, as well as dermatologic reactions ranging from rashes to Stevens-
Johnson syndrome,  toxic epidermal necrolysis and severe hepatotoxicity [1].  Purple glove
syndrome (PGS) is an atypical, adverse and a rare reaction to intravenous phenytoin. This
complication is mainly characterized by pain, edema and a dark purple-bluish discoloration,
typically located on the upper limb, distal to the intravenous access [2,3]. Moreover, pain can
be  present  in  all  stages.  What  is  really  important  is  that  PGS  can  develop  to  necrosis,
ischemia, vascular compression and compartment syndrome, resulting in the need of surgical
treatment [2]. The etiology is still unexplained but it is suspected that extravasation injury and
thrombotic incident can cause PGS [4]. Despite many theories, the pathophysiology of this
phenomenon still remains notional. Intravenous administration of phenytoin is recommended
for patients with status epilepticus, refractory to benzodiazepines, for patients with traumatic
intracranial injury or intracranial neoplasm [5,6].
History
Since 1956, phenytoin sodium has been used in the prevention and treatment of seizures as an
anticonvulsant.  Phenytoin  has  found  indication  for  treatment  of  status  epilepticus  as  the
second-line agent after IV benzodiazepines. Moreover,  this medicine is recommended by the
European  Federation  of  Neurological  Societies  (EFNS)  and  also  Epilepsy  Foundation  of
America  (EFA).  Since  1950,  there  have  been  many  reports  of  soft  tissue  injuries  or
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extravasation following administration of IV phenytoin.  An important report, that was first
published by Comer  et  al.  in  1984 brought  closer  the  adverse  effect  of  phenytoin,  some
specific symptoms were reported, such as  pain, rapid onset of discoloration, tissue necrosis
and also progressive tissue necrosis to the distal extremity through which the phenytoin was
intravenously  administered.  The  name  "purple  glove  syndrome"  (PGS)  appeared   in  the
publication  published  by  Hanna  in  1992.  PGS  was  characterized  by  following  IV
administration of phenytoin  delayed, soft tissue mutilation of the hand and forearm [1].  PGS
gets its term from the characteristic bluish colouration of the skin [7]. In 1996 FDA approved
the pro-drug of phenytoin, named fosphenytoin which found out to be  less probable to cause
PGS than phenytoin [1]. Fosphenytoin in comparison with phenytoin does not require ethanol
or propylene glycol and it is soluble in aqueous solutions [8]. In addition, it has been shown
that fosphenytoin is less toxic compared with phenytoin. Moreover, it can be given through
either intramuscular or intravenous injection and it is also less painful after extravasation [9].
Epidemiology
Observations show that not all patients who receive intravenous phenytoin develop PGS. It is
speculated that the most significant and preventable factor to lead the development of PGS
can  be  to  downplay  adherence  to  the  guidelines  for  intravenous  recommendations  of
phenytoin usage [10]. There are many risk factors that can have a significant impact on PGS,
like age - patients who are 60 years old and above are more likely to develop PGS. However,
Dilek Ulubaş et al. reported complication after intravenous phenytoin infusion in newborn and
the appearance of PGS [11].  Moreover,  patients who receive large or multiple doses of IV
phenytoin  are more predisposed to develop PGS .  Another less supported risk factor may be
the conditions that weaken vascular and skin integrity. Additionally, important risk factor is
high phenytoin infusion rates (estimated value >25 mg/min). It is considered that the diameter
of the catheter smaller than 20 gauge can also be a risk factor. Unfortunately,  there is no
consensus regarding the observation in the research of many researchers. As the reports of
O’Brien et  al.  present – the 89% patients developed  PGS after  usage of catheter  of size
greater than 20 gauge [12].  On the other hand Spengler et al. reported that catheter sizes
smaller than 20 gauge caused higher risk of PGS. [13]. The observation also shows that the
female gender is more likely to develop PGS [7]. The table summarizes risk factors that may
contribute to the development of PGS.
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Table 1 
Risk factors for Purple Glove Syndrome [1,2,3,4,5]
 the concentration of phenytoin 
 the rate of infusion 
 extravasation 
 chemical  irritation  by  solvents  (propylene  glycol,  sodium
hydroxide and ethanol) 
 drug-induced vasculitis 
 drug-induced vasoconstriction 
 genetic predisposition 
 use of an appropriate catheter (20-gauge or more) 
 elderly age group 
 female gender 
 conditions that weaken vascular and skin integrity 
 number of IV phenytoin doses received 
 high alkalinity of phenytoin 
Etiology and Pathophysiology
Purple glove syndrome has been described many times in both nursing and medical literature.
Unfortunately, despite the existence of many clinical reports about PGS, scientists are still not
able to clearly determine pathophysiological mechanism of this adverse effect.  Many theories
have been made to explain the etiology and pathophysiology of PGS.  Some of them implicate
the chemical properties of phenytoin [14-17], other site the physical damage induced by the
insertion of the intravenous catheter [18]. Other authors, though, proposed a drug-induced
vasculitis  [19,20]. In order to understand each point of view, it  is  good to know that  the
physiochemical properties of many drugs can indicate whether it will or not produce cellular
toxicity.   Phenytoin is  a chemically  weak,   poorly water  soluble acid,  which includes  an
alkaline compound soluble only at a high pH. Therefore, the solution is manufactured with
sodium hydroxide. What is more, a combination of propylene glycol and ethyl alcohol is also
used to increase solubility. These substances  are known tissue irritants itself [18]. Because of
high pH of 12, it may induce local vasoconstriction and finally result in vascular compromise,
disruption of the endothelial interstitial junctions and subsequent leakage of the drug into soft
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tissue.  After  then,  the  protein-bound  phenytoin  leads  to  increase  of   interstitial  oncotic
pressure, resulting in edema [14,16,21]. Phenytoin extravasation has also been explained as a
result  of  vascular  tears  from  intravenous  insertion  [18].  Scientists  has  also  taken  into
consideration  an  incidence  of  drug  precipitation  upon  mixing  with  blood  [17].  Another
interesting theory was about drug-induced vasculitis or mechanical vessel damage with micro
thrombi formation as a causative mechanism [20].  
Symptoms
Most commonly PGS is associated with upper extremities, however it has been many times
reported also in lower extremities and referred to as purple sock syndrome [8, 22, 23, 24]. The
hallmark of this syndrome is purplish discoloration and edema of the distal extremity, seen in
most cases. Pain is often present in this area but its existence can be omitted by patients due to
alterations in consciousness after a seizure. Skin changes can take a variety of forms ranging
from more common blistering, erythema and necrosis to deficits of function, such as sensor
changes and even paralysis [1]. PGS can be extremely painful and in severe cases it can be
even the cause of arterial  insufficiency and compartment  syndrome [23].  Generally,  three
stages of PGS has been described [14]. During the initial stage, blue to purple discoloration
around the intravenous insertion site is seen, usually appearing 2–12 h after administration of
phenytoin. The second, fully developed stage is characterized by the formation of edema and
worsening discoloration. The severity of the signs and symptoms may be dose-related. There
may  be  subsequent  blister  formation,  sloughing  and  reddish-purple  discoloration  of  the
affected  area.  Third  stage  lesions  show  a  decrease  in  size  of  the  discolored  area  and
diminished edema.  As for  the healing,  it  takes  place usually  from peripheral  towards  the
intravenous site. 
Diagnosis and treatment 
 The diagnosis of PGS is based on characteristic  symptoms and it  is suspected that these
symptoms occur after intravenous administration of phenytoin. It is necessary to exclude other
illnesses  e.g. cellulitis or necrotizing fasciitis [7].
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Table 2 








The treatment of PGS depends on intensification of symptoms and patient’s general condition.
A non-pharmacological therapies such as limb elevation, physiotherapy and reassurance to the
patient should be considered for everyone. What is more, affected arm should not be used to
draw blood and blood pressure measurement [4,7]. A pharmacological  treatment relies on
intravenous  heparin administration,  pain control,  nitroglycerine  application  to  the affected
area and brachial plexus block using local anaesthetics  like ropivacaine which may reduce
vasospasm. Pain relieving by blocking A and B fibres, brachial plexus blockade, sympathetic
blockade or stellate ganglion blockade should be perform by advanced anaesthesiologists. In
traumatic situation,  a surgical intervention may be required like fasciotomy or amputation
[3,4,7]. To prevent PGS it is recommended to use oral phenytoin whenever possible, slow
infusion rate of phenytoin less than 25mg/min, large cannula (20G or larger) in a large calibre
vein and suitable, small doses [3,4]. Medical care of the PGS patient require multidisciplinary
care  from  anaesthesiologist  (pain  control),  surgeon  (surgical  intervention),neurologist
(neurological assessment), dermatologist (dermatological consultation).
Table 3 
The 3 stages of purple glove syndrome [4]
Appearance Progression Resolution





Characteristic Bluish or purple 
discoloration of the 














Despite  the  existence  of  many  clinical  trials,  long  term  observations  and  scientific
speculations, PGS can still be challenging  for clinicians. In order to provide the highest level
of professional medical care it is necessary to make research and to spread knowledge about
PGS among medical staff.
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